Shots: The P-III MONALEESA trials (MONALEESA-2, 3,7) involved assessing of Kisqali (ribociclib) + endocrine therapy vs endocrine therapy alone in patients with visceral metastases in pre, peri- and postmenopausal women […]readmore
Tags : Novartis
Shots: Intellia to receive $10M upfront, milestones and royalties on sales. Novartis to get rights to Intellia’s CRISPR/Cas9 technology for the development of ex-vivo cell therapy using ocular stem cells […]readmore
Shots: The P-III SOLAR-1 trial assessed BYL719 (300 mg, qd) + fulvestrant (500 mg) vs PBO (fulvestrant) in 572 postmenopausal women in ratio (1:1) with PIK3CA-mutated HR+/HER2- advanced or metastatic […]readmore
Shots: The approval is based on the results of P-III PARADIGMS study assessing Gilenya (0.5mg/ 0.25mg, qd) vs Extavia (interferon beta-1a, qw) in 215 patients with MS aged 10 to […]readmore
Shots: The approval is based on P-III trial, involving assesment of Luxturna vs control group patients, with inherited retinal disease (caused due to mutation in both copies of the RPE65 […]readmore
Shots: The combination therapy recommendation of Kisqali plus endocrine therapy is based on results of P-III MONALEESA-7 and MONALEESA-3 trials assessing Kisqali vs endocrine therapy alone in women with HR+/HER2- […]readmore
Shots: The agreement involves a clinical trial assessing Novartis’s tropifexor and Pfizer’s compounds, including PF-05221304, PF-06865571 & PF-06835919 for treatment of NASH Novartis’ tropifexor (LJN452) is a Farnesoid X receptor […]readmore
Shots: The label update includes dosing flexibility of Cosentyx up to 300 mg based on clinical response & SC structural data of 24 wks., showing inhibition in progression of joint […]readmore
Shots: The P-IIIb Liberty study involves assessing of Aimovig (140 mg) vs PBO @12 wks. in patients with episodic migraine (4 to 14 migraine days/month) P-IIIb LIBERTY study results: reduction […]readmore
Shots: The P-III COMBI-AD trial involves assessing of Tafinlar (150mg bid) + Mekinist (2mg qd) vs PBO in 438 patients with BRAF V600-mutant stage III Melanoma for 44 months and […]readmore